共 50 条
Clinical management of type C hepatic encephalopathy
被引:16
|作者:
Ridola, Lorenzo
[1
]
Riggio, Oliviero
[1
]
Gioia, Stefania
[1
]
Faccioli, Jessica
[1
]
Nardelli, Silvia
[1
]
机构:
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Viale Univ 37, I-00185 Rome, Italy
关键词:
Hepatic encephalopathy;
minimal hepatic encephalopathy;
spontaneous portal-systemic shunts;
transjugular intrahepatic portosystemic shunt;
cirrhosis;
rifaximin;
non-absorbable disaccharides;
RANDOMIZED CONTROLLED-TRIAL;
INTRAHEPATIC PORTOSYSTEMIC SHUNT;
DOUBLE-BLIND;
PROGNOSTIC-SIGNIFICANCE;
PLUS LACTULOSE;
PROPHYLAXIS;
RIFAXIMIN;
CIRRHOSIS;
ALBUMIN;
STENTS;
D O I:
10.1177/2050640620909675
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Type-C hepatic encephalopathy is a complex neurological syndrome, characteristic of patients with liver disease, causing a wide and complex spectrum of nonspecific neurological and psychiatric manifestations, ranging from a subclinical entity, minimal hepatic encephalopathy, to a deep form in which a complete alteration of consciousness can be observed: overt hepatic encephalopathy. Overt hepatic encephalopathy occurs in 30-40% of patients. According to the time course, hepatic encephalopathy is subdivided into episodic, recurrent and persistent. Diagnostic strategies range from simple clinical scales to more complex psychometric and neurophysiological tools. Therapeutic options may vary between episodic hepatic encephalopathy, in which it is important to define and treat the precipitating factor and hepatic encephalopathy and secondary prophylaxis, where the standard of care is non-absorbable disaccharides and rifaximin. Grey areas and future needs remain the therapeutic approach to minimal hepatic encephalopathy and issues in the design of therapeutic studies for hepatic encephalopathy.
引用
收藏
页码:536 / 543
页数:8
相关论文